Curanex completes key Phyto-N milestones; plans Q4 2026 IND for ulcerative colitis

Curanex Pharmaceuticals Inc

Completed GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling studies.
28-day dose-range finding toxicology study in rats and dogs showed no adverse findings at any dose.
Expanded pipeline to include cancer cachexia; global market estimated at $2.54B in 2024.
Cash and equivalents of ~$4.0M as of March 31, 2026, sufficient for near-term development activities.
Targeting Q4 2026 IND submission for ulcerative colitis; Phase I trial to follow FDA review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.